A fixed-dose topical combination therapy containing a moderate-potency corticosteroid (Beclometasone dipropionate) and a broad-spectrum imidazole antifungal (Clotrimazole). It is primarily indicated for the treatment of inflammatory dermatoses complicated by or at high risk of superficial fungal infections, particularly in the humid Indian climate. The combination provides synergistic anti-inflammatory, antipruritic, and antifungal effects, addressing both the underlying inflammation and secondary or concomitant fungal overgrowth.
Adult: Apply a thin film to the affected and immediately surrounding area once or twice daily. Duration: Typically 1-2 weeks for fungal infections, up to 4 weeks for severe inflammatory conditions. Do not exceed 4 weeks without re-evaluation.
Note: 1. Wash and dry the affected area thoroughly. 2. Take a small amount (pea-sized for an area the size of the palm). 3. Gently rub in a thin layer until absorbed. 4. Do not bandage, wrap, or occlude the area unless specifically directed by a physician. 5. Wash hands after application unless hands are the treatment site. Avoid contact with eyes, nose, mouth, and broken skin.
Beclometasone: A synthetic glucocorticoid receptor agonist. It diffuses across cell membranes, binds to cytoplasmic glucocorticoid receptors, and translocates to the nucleus. This complex modulates gene transcription, leading to the synthesis of anti-inflammatory proteins (lipocortin) and inhibition of pro-inflammatory mediators (cytokines, leukotrienes, prostaglandins). It also causes vasoconstriction, reducing erythema and edema. Clotrimazole: Inhibits the fungal cytochrome P450-dependent enzyme lanosterol 14-α-demethylase. This disrupts the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. Accumulation of toxic methylated sterols leads to increased membrane permeability, leakage of cellular components, and fungal cell death.
Pregnancy: Pregnancy Category C (US FDA). Animal studies show teratogenicity with high systemic doses. Topical use should be limited to small areas for short durations, and only if clearly needed. Avoid extensive use, occlusion, or use on large areas. First-trimester use should be avoided.
Driving: No effect on driving ability.
| Other Topical Corticosteroids (e.g., Betamethasone, Mometasone) | Additive risk of local and systemic adverse effects, skin atrophy. | Major |
| Systemic CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Ritonavir) | May inhibit metabolism of systemically absorbed beclometasone, increasing risk of steroid side effects. | Moderate |
| Immunosuppressants (e.g., Tacrolimus, Pimecrolimus - topical) | Concomitant use may increase risk of skin infection; sequential use should be monitored. | Moderate |
Same composition (Beclometasone (0.025% w/w) + Clotrimazole (1% w/w)), different brands: